Risk Factors for Rituximab-Induced Interstitial Lung Diseases in Patients with Malignant Lymphoma
의약학 > 내과학
차승익 , 이소연 , 이용훈 , 유승수 , 이재희 , 이신엽 , 김창호 , 박재용
대한결핵 및 호흡기학회
대한결핵및호흡기학회 추계학술발표초록집 2012년, 제114권 169(총1페이지)
0y909846.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    30원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    Background: Rituximab, a key drug used in therapeutic strategies for treatment of CD20+ non-Hodgkin`s lymphoma, can cause drug-induced interstitial lung disease (ILD). Despite recent accumulation of data regarding the clinical features of rituximab-induced ILD, its risk factors have yet to be clarified. Objectives: The purpose of the present study was to investigate the clinical features of and risk factors for rituximab-induced ILD in patients with non-Hodgkin`s lymphoma who undergo treatment with rituximab-containing regimens. Methods: A retrospective study of patients with non-Hodgkin`s lymphoma treated with rituximab was conducted in a tertiary referral center in Korea. We compared various clinical parameters of patients with and without rituximab-induced ILD and determined its risk factors. Results: Of 264 patients with non-Hodgkin`s lymphoma who were treated with rituximab-containing chemotherapy regimens, nine (3.5%) were diagnosed as having rituximab-induced ILD, including clinically suspected cases (n=5). Based on clinical and radiologic findings, the most common pattern was organizing pneumonia (n=7 [78%]). Three patients (33%) for whom treatment failed died from respiratory failure caused by rituximab-induced ILD. Poor ECOG performance status and age were significant risk factor for rituximab-induced ILD (odds ratio [OR] 10.8, 95% confidence interval [CI] 1.6-74.8, p=0.016; and OR 1.1, 95% CI 0.0-1.2, p=0.048, respectively).
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일 help@reportshop.co.kr
    copyright (c) 2009 happynlife. steel All reserved.